Focal Segmental Glomerulosclerosis (FSGS): Causes, Pathology, and Clinical Impact

Focal segmental glomerulosclerosis (FSGS) is a histologic pattern of glomerular injury — not a single disease — defined by segmental (partial) sclerosis (scarring) affecting some (focal) glomeruli. It is a leading cause of nephrotic syndrome and CKD/ESRD.

Classification

CategoryExamples
Primary (Idiopathic)No identifiable cause. Presumed circulating permeability factor (e.g., suPAR). Often steroid-resistant.
Secondary / AdaptiveHyperfiltration from reduced nephron mass: obesity, prematurity, unilateral renal agenesis, reflux nephropathy, sickle cell, HIV (collapsing variant).
GeneticNPHS2 (podocin), ACTN4, TRPC6, INF2. Early onset, familial, steroid-resistant.
Drug/Toxin-InducedPamidronate, sirolimus, anabolic steroids, heroin, lithium.
ViralHIV (collapsing FSGS), parvovirus B19.

Histologic Variants (Columbia Classification)

  • Collapsing: Worst prognosis. Podocyte hyperplasia, capillary collapse. HIV, pamidronate, genetic.
  • Tip: Best steroid response. Sclerosis at tubular pole.
  • Cellular: Endocapillary hypercellularity.
  • Perihilar: Sclerosis at vascular pole. Common in adaptive.
  • Not Otherwise Specified (NOS): Most common.

Clinical Presentation

  • Nephrotic syndrome (heavy proteinuria >3.5 g/day, hypoalbuminemia, edema, hyperlipidemia) — 70% primary.
  • Subnephrotic proteinuria + microscopic hematuria + hypertension + declining GFR — secondary/genetic.

Diagnosis and Management

  • Renal biopsy required (LM, IF, EM). EM: foot process effacement (>80%).
  • Genetic testing if early onset, family history, steroid-resistant.
  • Primary FSGS: High-dose prednisone (16 weeks) → if resistant: calcineurin inhibitors (tacrolimus, cyclosporine), rituximab, mycophenolate, ACTH gel.
  • Secondary: Treat underlying cause + RAAS blockade (ACEi/ARB) — cornerstone.
  • Recurrence post-transplant: 30–50% (primary); plasmapheresis + rituximab prophylaxis.

FSGS is a spectrum. Accurate classification guides therapy and prognosis. Early RAAS blockade slows progression in all forms.

Multiple Sclerosis - Related Articles